Lidbree

Lidocaine, the active ingredient in Lidbree, is a local anesthetic presented as an unspecified strength/solution for intrauterine use. It provides rapid, reversible loss of sensation in the uterine lining during diagnostic and therapeutic procedures, helping to reduce patient discomfort and facilitate clinical interventions.

GNH USA supplies Lidbree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global clinical demand.

Lidbree (lidocaine) is employed in intrauterine procedures to achieve local anesthesia of the uterine cavity. - Hysteroscopic procedures: Provides analgesia and reduces uterine cramping during diagnostic or operative hysteroscopy. - Intrauterine device (IUD) insertion: Numbs the endometrial lining to lessen insertion pain. - Uterine surgery (e.g., polypectomy): Facilitates removal of intrauterine lesions by providing localized numbness.

Lidocaine administered intrauterinely may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Uterine cramping: transient painful contractions. - Nausea: mild stomach upset. - Dizziness: temporary light‑headedness. - Headache: mild to moderate pain. - Local irritation: burning or stinging at the application site. - Vaginal discharge: mild watery discharge.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Cardiovascular toxicity: hypotension, arrhythmias, or cardiac arrest. - Central nervous system toxicity: seizures or severe confusion. - Methemoglobinemia: reduced oxygen‑carrying capacity of blood. - Severe hypotension: sudden drop in blood pressure. - Respiratory depression: difficulty breathing.

When using Lidbree, clinicians should observe several precautionary measures to ensure patient safety and product integrity. - Allergy assessment: verify no known hypersensitivity to lidocaine or related amide anesthetics. - Minimum effective dose: use the lowest concentration that achieves adequate anesthesia. - Cardiovascular monitoring: observe heart rate and blood pressure during and after administration. - Hepatic impairment: exercise caution in patients with severe liver disease due to reduced metabolism. - Pregnancy and lactation: consider potential risks and limit use to situations where benefits outweigh risks. - Store at room temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Lidocaine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may cause additive cardiac toxicity. - Amiodarone: increases lidocaine plasma levels, raising risk of toxicity. - Cimetidine: inhibits hepatic metabolism, leading to higher lidocaine concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers (e.g., propranolol): may enhance lidocaine’s depressant effects on heart rate. - Calcium channel blockers (e.g., verapamil): can increase risk of hypotension. - Other local anesthetics: concurrent use may raise total anesthetic load. - Tricyclic antidepressants (e.g., amitriptyline): may potentiate CNS toxicity. - CYP3A4 inhibitors (e.g., erythromycin): may modestly elevate lidocaine levels.